tiprankstipranks
Prelude Therapeutics (PRLD)
NASDAQ:PRLD
US Market

Prelude Therapeutics (PRLD) Income Statement

Compare
134 Followers

Prelude Therapeutics Income Statement

Last quarter (Q3 2024), Prelude Therapeutics's total revenue was $3.00M, an increase of Infinity% from the same quarter last year. In Q3, Prelude Therapeutics's net income was $-32.27M. See Prelude Therapeutics’s key income statements, including revenue, expenses, profit, and income.
Income Statement
Dec 23Dec 22Dec 21Dec 20Dec 19
Total Revenue
$ 0.00$ 0.00$ 0.00$ 0.00$ 0.00
Gross Profit
$ -1.17M$ -3.04M$ -2.24M$ -542.00K$ -382.00K
Operating Expenses
$ 132.28M$ 123.54M$ 113.73M$ 58.76M$ 28.11M
Depreciation and Amortization
$ 1.17M$ 3.04M$ 2.24M$ 542.00K$ 382.00K
EBITDA
$ -131.11M$ -122.22M$ -112.82M$ -58.22M$ -27.73M
Operating Income
$ -132.28M$ -123.54M$ -113.73M$ -58.76M$ -28.11M
Other Income/Expenses
$ 10.45M$ 8.10M$ 2.04M$ 1.83M$ 539.00K
Pretax Income
$ -121.83M$ -115.44M$ -111.69M$ -56.93M$ -27.57M
Net Income
$ -121.83M$ -107.34M$ -110.78M$ -56.93M$ -27.57M
Per Share Metrics
$ ―$ ―$ ―$ ―$ ―
Basic EPS
$ -2.02$ -2.27$ -2.33$ -1.30$ -0.85
Diluted EPS
$ -2.02$ -2.27$ -2.33$ -1.30$ -0.85
Weighted Average Shares Outstanding
60.36M 47.37M 47.60M 43.71M 32.40M
Weighted Average Shares Outstanding (Diluted)
60.36M 47.37M 47.60M 43.71M 32.40M
Currency in USD

Prelude Therapeutics Earnings and Revenue History

What am I Missing?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis